Eagle Pharmaceuticals (EGRX)
2.1400  0.00 (0.00%)

Eagle Pharmaceuticals is a biopharmaceutical company that specializes in developing and commercializing innovative injectable pharmaceutical products. The company focuses on addressing the needs of patients and healthcare providers by creating improved formulations of existing medications and developing new therapies. Eagle Pharmaceuticals aims to enhance treatment options in critical areas such as oncology and critical care, thereby providing solutions that can improve patient outcomes and streamline delivery in healthcare settings. Through its commitment to research and development, Eagle Pharmaceuticals strives to bring safe and effective medications to the market.

SummaryNewsPress ReleasesChartHistorical
Previous Close2.140
Open-
Bid2.270
Ask2.330
Day's RangeN/A - N/A
52 Week Range2.140 - 6.810
Volume0
Market Cap27.17M
PE Ratio (TTM)2.352
EPS (TTM)0.9
Dividend & YieldN/A (N/A)
1 Month Average Volume-

News & Press Releases

12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · October 2, 2024
Crude Oil Edges Higher; ConAgra Posts Downbeat Earningsbenzinga.com
Via Benzinga · October 2, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · October 2, 2024
Dow Gains 100 Points; Joby Aviation Shares Spike Higherbenzinga.com
Via Benzinga · October 2, 2024
US Stocks Edge Lower; Private Employment Beats Expectationsbenzinga.com
Via Benzinga · October 2, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · May 22, 2024
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)
The Law Offices of Frank R. Cruz reminds investors of the upcoming February 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Eagle Pharmaceuticals, Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ: EGRX) securities between August 8, 2023 and November 28, 2023, inclusive (the “Class Period”).
By The Law Offices of Frank R. Cruz · Via Business Wire · February 8, 2024
EAGLE PHARMACEUTICALS 48 HOUR DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX.
By Faruqi & Faruqi LLP · Via GlobeNewswire · February 8, 2024
ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX
WHY: NEW YORK, NY - (NewMediaWire) - February 06, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
Via NewMediaWire · February 6, 2024
ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX
WHY: NEW YORK, NY - (NewMediaWire) - February 06, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
Via TheNewswire.com · February 6, 2024
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Pharmaceuticals, Golden Heaven, Inspire Medical, and Driven and Encourages Investors to Contact the Firm
NEW YORK, Feb. 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Golden Heaven Group Holdings Ltd. (NASDAQ: GDHG), Inspire Medical Systems, Inc. (NYSE: INSP), and Driven Brands Holdings, Inc. (NASDAQ: DRVN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · February 4, 2024
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX
NEW YORK, Feb. 04, 2024 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 4, 2024
ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 2, 2024
ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX
WHY: NEW YORK, NY - (NewMediaWire) - February 02, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
Via TheNewswire.com · February 2, 2024
ROSEN, A LEADING LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX
NEWE YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 1, 2024
EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX.
By Faruqi & Faruqi LLP · Via GlobeNewswire · February 1, 2024
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Microvast, Eagle Pharmaceuticals, Golden Heaven, and Inspire Medical and Encourages Investors to Contact the Firm
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Microvast Holdings, Inc. (NASDAQ: MVST), Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Golden Heaven Group Holdings Ltd. (NASDAQ: GDHG), and Inspire Medical Systems, Inc. (NYSE: INSP). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 31, 2024
ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 29, 2024
ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX
WHY: NEW YORK, NY - (NewMediaWire) - January 29, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
Via TheNewswire.com · January 29, 2024
ROSEN, A TOP RANKED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 28, 2024
ROSEN, A TOP RANKED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX
WHY: NEW YORK, NY - (NewMediaWire) - January 28, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023, both dates inclusive (the “Class Period”), of the important February 9, 2024 lead plaintiff deadline.
Via TheNewswire.com · January 28, 2024
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Microvast, Eagle Pharmaceuticals, Golden Heaven, and Inspire Medical and Encourages Investors to Contact the Firm
NEW YORK, Jan. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Microvast Holdings, Inc. (NASDAQ: MVST), Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Golden Heaven Group Holdings Ltd. (NASDAQ: GDHG), and Inspire Medical Systems, Inc. (NYSE: INSP). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 27, 2024
EAGLE PHARMACEUTICALS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX.
By Faruqi & Faruqi LLP · Via GlobeNewswire · January 24, 2024
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fisker, Microvast, Eagle Pharmaceuticals, and Golden Heaven and Encourages Investors to Contact the Firm
NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Fisker Inc. (NYSE: FSR), Microvast Holdings, Inc. (NASDAQ: MVST), Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), and Golden Heaven Group Holdings Ltd. (NASDAQ: GDHG). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 23, 2024
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EGRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 23, 2024